MedTrace Logo

Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

NCT05965505 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-08-01

No results posted yet for this study

Summary

This is an open-label, multicenter, phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in adult subjects with Relapsed/Refractory Non-Hodgkin Lymphomas.

Conditions

  • Relapsed or Refractory Non-Hodgkin's Lymphoma

Interventions

DRUG

AXT-1003

AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.

Sponsors & Collaborators

  • Axter Therapeutics (Beijing) Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Yanfang Guo · Axter Therapeutics (Beijing) Co., Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-11
Primary Completion
2023-09-05
Completion
2023-09-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05965505 on ClinicalTrials.gov